Oxogestone

Oxogestone (INN), also known as 20β-hydroxy-19-norprogesterone, is a progestin of the 19-norprogesterone group which was synthesized in 1953 and was developed as an injectable hormonal contraceptive in the early 1970s but was never marketed.[1][2][3][4][5] A C20β phenylpropionate derivative, oxogestone phenpropionate, also exists.[1]

Oxogestone
Clinical data
Other namesOxagestone; Oxagesterone; Oxogesterone; 20β-Hydroxy-19-norprogesterone; (20R)-20-Hydroxy-19-norpregn-4-en-3-one
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H30O2
Molar mass302.458 g/mol g·mol−1
3D model (JSmol)

References
  1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 919–. ISBN 978-1-4757-2085-3.
  2. George W.A Milne (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1577–. ISBN 978-1-351-78989-9.
  3. Farkas M, Szontágh FE (1972). "Clinical experiences concerning the intramuscular contraceptive oxogestone". Acta Eur. Fertil. 3 (1): 37–43. PMID 4679651.
  4. Ruíz Velasco V, Alisedo Aparicio LE (1972). "[Side effects of depot contraceptives]". Prensa Med Mex (in Spanish). 37 (1): 25–9. PMID 5032612.
  5. Bassol, Susana; Garza-Flores, Josue (1994). "Review of ovulation return upon discontinuation of once-a-month injectable contraceptives". Contraception. 49 (5): 441–453. doi:10.1016/0010-7824(94)90003-5. ISSN 0010-7824. PMID 8045131.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.